Almirall at the next hybrid EADV Congress 2024, reinforcing our commitment to Medical Dermatology. This year the congress will be hosted in the city of Amsterdam (Netherlands) from 25th to 28th September 2024.

Our Symposia

A range of Scientific Sessions presenting the latest evidence-based data at the EADV Congress 2024. The sessions will be placed between two different days on Thursday  26th and Friday 27th. Discover the next inspiring talks in derma industry.

Thursday, September 26th 2024

From 17:45 h.
to 18:45 h. CEST

SAT 11.04

Room G104 – 105
Level 1

Add to Calendar

Satellite Symposium on psoriasis

Advancing Psoriasis Management for
Long-Term Patient Outcomes

Chair

Prof. Dr. Diamant Thaçi

Germany

Prof. Dr. Anna López-Ferrer

Spain

Prof. Dr. Ulrich Mrowietz

Germany

17:45 h.

Introduction

Prof. Dr. Diamant Thaçi

17:50 h.

Long-Term Treatment Individualization:
A Journey to Better Patient Outcomes

Prof. Dr. Anna López-Ferrer

18:05 h.

What really matters to the patient: understanding patient goals and preferences

Prof. Dr. Ulrich Mrowietz

18:20 h.

Practical Strategies for Clinical Success

Prof. Dr. Diamant Thaçi

18:35 h.

Discussion and Q&A

All the faculty

18:40 h.

Closing

Prof. Dr. Diamant Thaçi

  • See the complete agenda
  • Close the complete agenda

Reasons to not miss out
this session

The session highlights the significance of tailoring treatments to individual patients in clinical practice in the long-term journey, leading to improved treatment outcomes. Experts will delve into the recent findings from real world evidence, emphasizing the importance of understanding patient goals and preferences. Additionally, through an interactive session, the experts will offer practical recommendations for applying this personalized approach in clinical settings.

This session has been organised and funded by Almirall SA and may mention Almirall products. This session’s recording will be available on-demand at the Congress platform for your convenience.
Access for this session is limited and under invitation only.

Friday, September 27th 2024

From 13:00 h.
to 14:00 h. CEST

SAT 11.06

Room G104 – 105
Level 1

Add to Calendar

Satellite Symposium on atopic dermatitis

Precision in AD: how lebrikizumab▼
is changing the treatment paradigm

Chair

Prof. Dr. Marjolein de Bruin-Weller

The Netherlands

Dr. Andrew Blauvelt

United States

Prof. Dr. Sascha
Gerdes

Germany

13:00 h.

Welcome & introduction

Prof. Dr. Marjolein de Bruin-Weller

13:03 h.

The landscape in AD has evolved, but 
are we there yet?

Prof. Dr. Marjolein de Bruin-Weller

13:13 h.

Expert insights on lebrikizumab▼ clinical evidence

Dr. Andrew Blauvelt

13:33 h.

How does real-life look like for patients treated with lebrikizumab▼?

Prof. Dr. Sascha Gerdes

13:48 h.

Panel discussion

All the faculty

13:58 h.

Closing

Prof. Dr. Marjolein de Bruin-Weller

  • See the complete agenda
  • Close the complete agenda

Reasons to not miss out
this session

Three atopic dermatitis experts will debate on the remaining unmet needs in AD despite the existing approved treatments for moderate to severe AD, will provide insights on the MoA and clinical data of lebrikizumab▼, and will present clinical cases treated with lebrikizumab▼.

▼ This medicinal product is subject to additional monitoring.
Lebrikizumab is approved by EMA and is currently authorised for commercialisation in Germany and the United Kingdom. Click here for lebrikizumab SmPC.

All adverse events must be reported. Please refer to the adverse event reporting framework for your local supervisory authority.
These sessions are organised and funded by Almirall. Almirall products may be discussed.
This session’s recording will be available on-demand at the Congress platform for your convenience. Access for this session is limited and under invitation only.

Almirall’s faculty at EADV Congress 2024

Prof. Dr. Diamant Thaçi

Lübeck, Germany

Advancing Psoriasis Management
for Long-Term Patient Outcomes

Thursday, September 26th 2024
From 17:45 h. to 18:45 h. CEST

Prof. Dr. Anna López-Ferrer

Barcelona, Spain

Advancing Psoriasis Management
for Long-Term Patient Outcomes

Thursday, September 26th 2024
From 17:45 h. to 18:45 h. CEST

Prof. Dr. Ulrich Mrowietz

Kiel, Germany

Advancing Psoriasis Management
for Long-Term Patient Outcomes

Thursday, September 26th 2024
From 17:45 h. to 18:45 h. CEST

Prof. Dr. Marjolein de Bruin-Weller

Utrech, The Netherlands

Precision in AD: how lebrikizumab▼ is changing the treatment paradigm

Friday, September 27th 2024
From 13:00 h. to 14:00 h. CEST

Dr. Andrew Blauvelt

Lake Oswego, United States

Precision in AD: how lebrikizumab▼ is changing the treatment paradigm

Friday, September 27th 2024
From 13:00 h. to 14:00 h. CEST

Prof. Dr. Sascha Gerdes

Kiel, Germany

Precision in AD: how lebrikizumab▼ is changing the treatment paradigm

Friday, September 27th 2024
From 13:00 h. to 14:00 h. CEST

Any questions?

Contact us if you need more information related to Almirall portfolio.

Medical Information

Prof. Dr. Sascha Gerdes​

Lübeck, Germany

Satellite Symposium on atopic dermatitis

Advancing Psoriasis Management for Long-Term Patient Outcomes

Thursday, Sept. 26th 2024 From 17:45 to 18:45 CEST

Biography

Professor Dr Diamant Thaçi graduated in 1989 with a medical degree and specialized in dermatology and venereology 1995 at the Department of Dermatology and Venerology at Johann Wolfgang Goethe University in Frankfurt, Germany. Dr Thaçi has held the roles of Senior Consulting Specialist in Dermatology, Director of Clinical Research, Head of Photodermatology division from 1997-2011. In 2011 he was appointed as Associate Professor of Dermatology, Venereology and Allergology at the Goethe University in Frankfurt/Main Germany. Since 2013 he is a director and full university professor at the Institute and Comprehensive Center Inflammation Medicine University of Lübeck, Germany. He is chairman of inflammatory board at the university hospital Schleswig-Holstein campus Luebeck.

Dr Thagi’s research experience covers immunological work in basic research and as well, all stages of clinical drug development especially in chronic inflammatory skin diseases like psoriasis, atopic dermatitis, hidradenitis suppurativa etc.
Dr Thaçi has been a recipient of the Theodor-Stern Foundation Award in for excellent clinical research. He has been involved in numerous investigator-driven trials, and acted as main investigator on large numbers of national and international multicentre trials. In addition to his clinical commitments, Dr Thaçi also lectures on dermatology, cross section immunology/ microbiology and publishing numerous articles in high reputation journals like New England Journal of Medicine or Lancet.
Editor, co-editor, member of editorial board for several scientific journals and serves as a scientific reviewer of dermatological but also general medicine journals. He is a member of steering committee of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), active member of International Psoriasis Council (IPC), International Eczema council (IEC), and SPIN – Skin Inflammation & Psoriasis International Network (SPIN).

Prof. Dr. Anna López-Ferrer

Barcelona, Spain

Satellite Symposium on atopic dermatitis

Advancing Psoriasis Management for Long-Term Patient Outcomes

Thursday, Sept. 26th 2024 From 17:45 to 18:45 CEST

Biography

Dr. Anna López Ferrer is a Dermatology Specialist at the Dermatology Department of the Hospital de la Santa Creu i Sant Pau in Barcelona and holds a PhD in Biochemistry from the University of Barcelona. She is currently a member of the Board of Directors of the Spanish Academy of Dermatology and Venereology, Associate Professor at the Universitat Autónoma de Barcelona and is the Coordinator of the Psoriasis Group of the AEDV (Spanish Academy of Dermatology).

She works in the Psoriasis Unit of the Department of Dermatology and since June 2012, together with the Department of Rheumatology, she created a joint clinic to work with patients with psoriasis and psoriatic arthritis. Her main focus is on the early diagnosis of psoriatic arthritis in patients with psoriasis and the optimisation of treatment for these patients.

Dr. López Ferrer is a member of the Spanish Society of Dermatology (AEDV), the European Academy of Dermatology and Venereology (EADV), the Group for Research of Psoriasis and Psoriatic Arthritis (GRAPPA), and is a Councilor of the International Psoriasis Council (IPC). She has authored or co-authored multiple scientific articles and has participated in multiple national and international clinical trials on psoriasis.

Prof. Dr. Ulrich Mrowietz

Kiel, Germany

Satellite Symposium on atopic dermatitis

Advancing Psoriasis Management for Long-Term Patient Outcomes

Thursday, Sept. 26th 2024 From 17:45 to 18:45 CEST

Biography

Dr. Ulrich Mrowietz is a Professor of Dermatology and the founder of the Psoriasis Center in the Department of Dermatology at the University Medical Center Schleswig-Holstein, Campus Kiel, Germany. His main research areas in psoriasis include management strategies, drug development, and basic research. The Psoriasis Center provides a large clinical trial unit and is part of the Comprehensive Center for Inflammation Medicine at the Kiel Campus.

Professor Mrowietz is the author or co-author of more than 395 peer-reviewed publications listed in the Medline database and numerous other publications in the field. In addition, he is the author of chapters in multiple psoriasis textbooks, including Braun-Falco’s Dermatology and Venerology.

Prof. Dr. Marjolein de Bruin-Weller

Utrech, The Netherlands

Satellite Symposium on atopic dermatitis

Precision in AD: how lebrikizumab is changing the treatment paradigm

Friday, Sept. 27th 2024 From 13:00 to 14:00 CEST

Biography

Marjolein de Bruin-Weller is full Professor and head of the National Expertise Center of Atopic Dermatitis, situated in the dpt. of Dermatology and Allergology of the University Medical Center Utrecht, The Netherlands.

Her major interest is clinical and translational research in atopic dermatitis. She is the principal investigator in several clinical trials and investigator-initiated studies focused on difficult to treat atopic dermatitis and systemic immunosuppressive and immuno-modulating treatment.

In 2018 she initiated the BioDay Registry in the Netherlands together with dr. Marie-Louise Schuttelaar from the department of Dermatology of the University Medical Center of Groningen. This registry is focused on the new advanced systemic treatments in atopic dermatitis and includes a lot of data regarding atopic dermatitis (signs, symptoms, quality of life, work impairment) as well as data on atopic co-morbidities. Currently 1900 patients from 18 sites in the Netherlands are included in the BioDay registry.

Together with Femke van Wijk, professor of tissue immunology at the Center of Translational Immunology (CTI) of the University Medical Center Utrecht, she leads the translational Atopic Dermatitis research group.

Marjolein de Bruin-Weller is chair of the Expertise group Allergy and Eczema of the Dutch Society of Dermatology and Venereology and member of the European Task Force of Atopic Dermatitis (ETFAD), the International Eczema Council (IEC) and the GA’LEN ADCARE Task Force. She is chair of the advisory board of the Dutch Patient Society for Atopic Dermatitis (VMCE) and member/chair of several Dutch committees regarding advanced systemic treatments in inflammatory diseases.

Dr. Andrew Blauvelt

Lake Oswego, United States

Satellite Symposium on atopic dermatitis

Precision in AD: how lebrikizumab is changing the treatment paradigm

Friday, Sept. 27th 2024 From 13:00 to 14:00 CEST

Biography

Dr. Blauvelt is a Consultant at Blauvelt Consulting, LLC. He received his undergraduate degree in electrical engineering at Purdue University, his medical degree at Michigan State University, and a healthcare MBA at Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Dr. Steve Katz at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland VA Medical Center (Chief) as well as being Owner and President of Oregon Medical Research Center (OMRC) from 2013-2022. Dr. Blauvelt’s research and clinical expertise has been in Langerhans cell biology, T cell immunology, virology, psoriasis, and atopic dermatitis. He has published over 375 papers and spoken across the country and world on these topics. Within psoriasis research, his laboratory published key papers on the role of IL-23/Th17 biology in this disease. In recent years while at OMRC, he has been the international lead/senior investigator on a number of important clinical trials, including PSTELLAR, FEATURE, CLEAR, IXORA-R, VOYAGE 1, ECLIPSE, IMMhance, ABLE 1, BE ABLE 2, BE READY, BE RADIANT, OASIS-1, POETYK PSO-1, CHRONOS, ECZTEND, JADE REGIMEN, HEADS UP, ADhere, STRATUM, and KNOCKOUT. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council, and the International Eczema Council. In 2023, he became Chair of the Medical Board for the National Psoriasis Foundation, an organization he has worked closely with for over 20 years in a variety of capacities. For the past 3 years, Dr. Blauvelt made the lists of Highly Cited Researchers, representing the top 1% of cited scientists in the world. 

Prof. Dr. Sascha Gerdes

Kiel, Germany

Satellite Symposium on atopic dermatitis

Precision in AD: how lebrikizumab is changing the treatment paradigm

Friday, Sept. 27th 2024 From 13:00 to 14:00 CEST

Biography

Department of Dermatology, Venereology, and Allergology, Center for Inflammatory Skin Diseases, University Medical Center

Schleswig-Holstein Campus Kiel, Kiel, Germany.

Sascha Gerdes is Professor of Dermatology, Venereology, Allergology and Immunology in the Department of Dermatology, Venereology, and Allergology at the Center for Inflammatory Skin Diseases, University Medical Center Schleswig-Holstein in Kiel, Germany. Since 2012, he has also been Head of the Department for Clinical Trials at the Center. Dr Gerdes earned his degree in medicine at the Christian-Albrechts University of Kiel Medical School in Kiel in 2004 and his MD degree in 2006 as well as his Habilitation in 2015 at the Institute of Human Genetics of the Christian-Albrechts University of Kiel and at the Department of Dermatology, Venereology and Allergology.

Dr Gerdes’ major research interests include inflammatory skin diseases and autoimmune dermatoses with a special interest in psoriasis. He has served as Sub-Investigator and Principal Investigator in multiple international, multicentre clinical trials in patients with moderate-to-severe plaque-type psoriasis, atopic dermatitis, scalp psoriasis, herpes simplex, and autoimmune dermatoses. He has earned a number of awards, including the Wyeth BioPharma Research Promotion Dermatology 2008, the AbbVie Research Award Dermatology 2013, and the German Psoriasis Award 2014 – a Research Award of the German Dermatological Society (DDG) – and is a member of the Scientific Advisory Board of the German Psoriasis Association and a member of the DDG, the ADF (Arbeitsgemeinschaft Dermatologische Forschung), and the BVDD (Professional Association of German Dermatologists). To date, Dr Gerdes has 130 published peer-reviewed articles referenced in the Medline database.

Welcome to almiralldermatologycongress.com

The information provided on this website is intended for use by healthcare professionals qualified to prescribe and supply medications, thus requiring specific scientific knowledge and training to interpret it correctly.

I am not an HCP

I am an HCP

Leaving almiralldermatologycongress.com

Dear User,

You are about to leave almiralldermatologycongress.com since your request does not correspond to Almirall’s content related to EADV Congress 2024.

We will redirect you to almirall.com

Thanks for your visit.

Come back soon!

Leave

Stay

Prof. Dirschka

Germany

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Thomas Dirschka graduated in medicine at the University of Bochum, Germany in 1993 and has since specialised in dermatology. After a period of research at the Medical College of Virginia in the USA, Professor Dirschka returned to Germany and did further research work before entering private dermatological practice.

His areas of special interest include prevention and treatment of skin cancer, inflammatory skin diseases, allergy,dermatopathology, and aesthetic dermatology.

He is actively involved in clinical study programmes and clinical trials to determine the efficacy and safety of novel treatments for dermatological conditions. In 2000 Professor Dirschka founded CentroDerm®, a company for research and development in the field of dermatology. In this context he runs a skin physiology laboratory for investigation of skin barrier function, skin sensitivity and effects of topical applications on the skin.

Prof. Fargnoli

Italy

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Maria Concetta Fargnoli is Full Professor of Dermatology and Chair of the Department of Dermatology at the University of L’Aquila, Italy. She received her medical degree in 1992 at the University of Rome “Tor Vergata”, completed her residency in Dermatology and Venereology at the University of L’Aquila in 1998 and started her academic career in 1999. She is the Director of the Laboratory of Molecular Biology in Dermato-Oncology, Director of the Interdepartmental Centre of Molecular Diagnostics and Advanced Therapies, Faculty of the PhD Program in Experimental Medicine at the University of L’Aquila and Coordinator of the Skin Cancer Tumor Board.

Her clinical and experimental research interests include epidemiology and molecular genetics of melanoma and non-melanoma skin cancers, non-invasive diagnostic techniques in dermatology, new therapeutic interventions for inflammatory and neoplastic skin diseases. She is actively involved in conducting clinical trials primarily focusing on non-melanoma skin cancers, psoriasis, atopic dermatitis and prurigo nodularis.

She has published 265 peer-reviewed scientific papers, contributed to many book chapters and lectured at national and international meetings. Prof. Fargnoli acts as reviewer of international journals on dermatology, oncology and genetics.

Prof. Fargnoli is currently VicePresident of the Italian Society of Dermatology (SIDeMaST) and has been board member, secretary, coordinator of the Group of Experimental Research and Bioengeneering in Dermatology and coordinator of the Scientific Committee of SIDeMaST.

Dr. Boada

Spain

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Dr. Aram Boada (Barcelona, 1979) is a specialist in Dermatology and Venereology (2008) and PhD degree from the Universitat Autònoma de Barcelona (2020). He works as Section Chief and Melanoma Unit Coordinator of the Dermatology Department of Hospital Universitari Germans Trias i Pujol in Badalona (Barcelona, Spain). His main fields of research are Dermato-Oncology (melanoma, field cancerization and cutaneous toxicities of oncologic treatments) with more than 100 publications and conference communications.